Intuitive Surgical (ISRG) 2024 Wells Fargo Healthcare Conference summary

Product innovation and launch updates

• Da Vinci 5 placements reached 70 in Q2, mainly with experienced surgeons to gather feedback on integration, autonomy, and ergonomics.

• New technologies like force feedback and Case Insights are in early stages, with supply constraints but strong surgeon interest.

• Planned hardware and software upgrades in the second half include Hub media management, telepresence, and skill simulator integration.

• Telepresence capability is developed in-house and used for case observations.

• Limited launch of da Vinci 5 will extend into early 2025, with broad launch and trade-ins expected around mid-2025.

Market dynamics and system placements

• Q2 saw 341 global system placements, up 18% net new, with no discernible U.S. pause ahead of da Vinci 5 rollout.

• Europe experienced lower placements due to government health budget pressures, especially in Germany and the U.K.

• China placements reflect delayed tenders and ongoing anti-corruption efforts, with no expected benefit from government stimulus.

• U.S. market remains stable, with most placements via lease arrangements, reducing capital budget sensitivity.

• Trade-in credits for Xi to da Vinci 5 expected to be higher than previous cycles, but specifics are not disclosed.

Financial performance and outlook

• Q2 gross margin was 70% pro forma, driven by better supplier pricing and logistics; second half expected to be flat due to rising depreciation.

• Significant CapEx in recent years will increase depreciation expense, impacting margins in 2025.

• Operating margin reached 35% in the first half of 2024, with a medium-term target of 35-40%.

• Trade-ins are expected to be a margin tailwind over the multiyear period.

• Gross margin for da Vinci 5 is currently below Xi but targeted to reach similar levels within three to five years.